"Surgery should be performed using as often as possible surgical mitral valve repair, as this treatment has shown safety, efficacy and good long-term results," says French Prof Alec Vahanian on Monday, the third ESC day.
Transapical aortic valve implantation (TA-AVI) is a new therapeutic strategy, which has been implemented successfully into clinical practice in several hundred patients suffering symptomatic aortic stenosis and an increase perioperative risk during the past two years. The Edwards SAPIEN™ prosthesis has been used.
Catheter ablation is still associated with a substantial amount of complications, and more failure then sometimes reported. Perforation with catheters is especially important in atrial fibrillation. Robotic navigation could reduce these complications.
The BACH (Biomarkers in Acute Congestive Heart Failure) trail, an international, multi-marker study, analysed the diagnostic and prognostic precision of new biomarkers in patients with dyspnea (Shortness of Breath).
Intima media thickness (IMT) is a valuable research tool that can be used as surrogate end points in clinical trails, says Professor Stefan Agewall.
Professor C Mueller adressed the issue of new biomarkers in acute cardiac care on the ESC on Monday, 1st September. Read his comment in the following.
Since Rofecoxib (Vioxx) was withdrawn from the worldwide market based on the safety findings of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study, the uncertainty around the cardiovascular safety of NSAIDs and COX-2 inhibitors remains and leaves practitioners with difficult management decisions for the hundreds of millions of patients worldwide who continue to require pain-relieving…
The Acuson SC2000 volume imaging ultrasound system - reported to be the first system in the world to acquire non-stitched real-time full-volume 3-D images of the heart in one single heart cycle - is launched at the ESC meeting in Munich.
Recent studies have shown that overweight and obesity during childhood and adolescence have a negative impact on the functioning of the internal walls of the arteries, paving the way to the development of an arteriosclerotic disease from an increasingly early age.
Under the banner Hear today the heartbeats of tomorrow, at this year's ESC meeting GE Healthcare will showcase its latest cardiology technology for the management of cardiovascular disease (CVD) as well as several new products.
Pegasus/Heartview LLC has announced that clinical studies of its HeartVue 6S Heart Screening System - which obtained CE Mark Approval in Europe almost two years ago - have been completed according to FDA guidelines, as a pre-marketing condition for release in the USA.
St. Jude Medical, Inc. has received European CE Mark approval and US Food and Drug Administration (FDA) clearance for its Epicor LP cardiac ablation system, a second generation technology that uses HIFU (high intensity focused ultrasound) for surgical ablation of cardiac tissue to disrupt abnormal cardiac electrical impulses.
Among the many aims of the Heart Failure Association of the ESC is the establishment of networks for the HF management, education and research.
The ageing population and growing risk factors have made a significant impact on driving up the number of registered heart failure (HF) cases. Existing pharmacological strategies are improving the survival rates of acute and early-stage HF patients, ironically providing a growing body of patients with progression of the disease to HF.
While treadmill exercise stress testing is essential to detect cardiovascular disease, gaining clear cardiac images at peak stress level are not easy to gain using standard testing procedures. Now, however, researchers at the Ohio State University Medical Centre have designed equipment to provide high-resolution cardiac images at a critical testing stage, with results in under one hour.
The diagnostic work-up of syncope patients often raises the question of how much diagnosis is necessary and what examination methods are really needed. To save time, specialists recommend focusing on determining whether the syncope may be caused by a cardiac problem - a question answered quite easily in many cases. Karl Eberius MD, European Hospital's new correspondent, discussed advice for…
Countries vary widely in their capacity to manage hypertension, but globally the majority of diagnosed hypertensives is inadequately controlled. Not treated it can cause cardiovascular disease (CVD), myocardial infarction and stroke. According to the WHO, hypertension is estimated to cause 4.5% of the current global disease burden and is as prevalent in many developing countries as in the…
What is the role of vascular ultrasound in stroke prevention? Asked by Karoline Laarmann of European Hospital, Professor Christian Arning MD, Medical Director of the Neurology Department at Asklepios Klinik Wandsbek, Germany, and Deputy Chairman of the German Society of Ultrasound in Medicine (DEGUM), gave an unequivocal answer: crucial - but only if the sonographer is properly qualified.
An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level. Molecular imaging allows for unique insights into specific disease mechanisms and holds great promise to change the practice of cardiovascular medicine by facilitating early disease detection,…
London, UK - A Hansen Sensei* robot has been used to perform vascular surgery on a 78-year-old patient for an aneurysm that would have been thought too high-risk for conventional surgery.
Bad economic conditions, e.g. a recession, at the time of birth may lead to a higher risk of cardiovascular mortality much later in life, according to a recent study published by researchers at the Institute for the Study of Labour (IZA) in Bonn.
Royal Philips Electronics is to lead `euHeart´, the new European Union (EU) funded research project that aims to improve CVD diagnosis, therapy planning and treatment.
This year sees the fifth anniversary of EuroPRevent.
Cardiologist Dr Malissa Wood, of the Massachusetts General Hospital, Boston, USA, has reported that a study of Olympic athletes, using GE Healthcare's Vivid I cardiac compact ultrasound technology, has allowed the medical research team in Beijing to identify healthy patterns of heart enlargement that can differentiate it from hypertrophic cardiomyopathy.
A new educational website specifically for heart failure patients, their families and carers, has been set up by the Heart Failure Association of the European Society of Cardiology.